Last reviewed · How we verify

NCT06379295: CALCOTEP

Coronary Artery Calcification Assessed on PET Scanner (PET : Positron Emission Tomography)

Completed Last updated 1 November 2024
What this trial tests

trial testing Questionnaire in Coronary Artery Disease in 200 participants. Completed in 22 July 2024.

Timeline
6 June 2024
Primary endpoint
22 July 2024
22 July 2024

Quick facts

Lead sponsorCentre Hospitalier Régional d'Orléans
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date6 June 2024
Primary completion22 July 2024
Estimated completion22 July 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Régional d'Orléans

Who can join

18 and older, any sex, with Coronary Artery Disease or Coronary Artery Calcification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Calcification artery calcium (CAC) scoring is a valuable tool for determining the risk of major adverse cardiac events. It was found that CAC can be quantitatively assessed, by manual scoring or using deep-learning, on low-dose non electrocardiogram-gated, contrast-enhanced or non-enhanced computed tomography (CT-scan) performed in association of PET acquisition, with a good agreement with standard scans. The purpose of this study is to determine the impact of a systematic coronary artery calcification evaluation in patients undergoing flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging to improve primary prevention of cardiovascular diseases. A visual calcification artery calcium assessment will be made for each patient, dividing them into four groups: none, mild, moderate or heavy calcification artery calcium. When possible, a calcification artery calcium score will be computed. Each patient will complete a questionnaire to collect risk factors, history of cardiovascular diseases and medications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Calcium scoring during 18F-FDG PET/CT in cancer indications: Improving cardiovascular risk stratification and prevention.
    Mazet R, Torossian N, Wanneveich M, Metrard G, et al · · 2025 · cited 1× · PMID 41166292 · DOI 10.1371/journal.pone.0335249

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Centre Hospitalier Régional d'Orléans trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06379295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing